Recent 8-K filings for CARL
Highest-materiality recent filing
Carlsmed closes IPO, adopts amended charter and bylaws effective July 24, 2025
- IPO closed on July 24, 2025; amended and restated certificate of incorporation and bylaws effective immediately prior to closing.
- Governance provisions include classified board, supermajority voting, and exclusive forum as described in final prospectus filed July 22, 2025.
-
Carlsmed Q1 revenue $16.1M (+58% YoY); raises FY2026 guidance to $72-77M
Revenue $16.1M, up 58% YoY from $10.2M; gross margin 77.1% vs 74.9%.
-
Carlsmed Q4 revenue $15.2M (+61% YoY); FY rev $50.5M (+86%); guides FY2026 $70-75M
Q4 rev $15.2M (+61% YoY), FY rev $50.5M (+86% YoY). Gross margin 76.5% Q4, 75.3% FY.
-
Carlsmed reports Q4 revenue ~$15.2M (+61% YoY); FY2025 ~$50.5M (+86% YoY)
Preliminary Q4 2025 revenue of ~$15.2M, 61% increase over Q4 2024.
-
Carlsmed Q3 revenue $13.1M (up 98% YoY); raises FY2025 guidance to $49M-$50M
Gross margin expanded to 75.9% from 72.8%; net loss of $8.5M vs $7.8M a year ago.
-
Term loan of up to $50M ($32.5M immediate, plus $7.5M and $10M upon achieving $60M and $90M trailing revenue milestones) with interest at Prime+0.25% (floor 5.25%).
-
Carlsmed Q2 revenue $12.1M (+99% YoY); raises FY guidance to $45.5M-$47.5M
Q2 revenue $12.1M, up 99% YoY; gross margin 73.4%; net loss $6.8M.
-
Carlsmed closes IPO, adopts amended charter and bylaws effective July 24, 2025
IPO closed on July 24, 2025; amended and restated certificate of incorporation and bylaws effective immediately prior to closing.
Earnings & guidance
Materiality & sentiment trend
Max materiality 1.00 · Median 0.75 · Most common event earnings